Noncoding RNA as therapeutic targets for hepatocellular carcinoma

Seminars in Liver Disease

Volumn 35, Issue 1, 2015, Pages 63-74

  George, Joseph ^a   Patel, Tushar ^a  

^a MAYO CLINIC   (United States)

Author keywords

biomarker; hepatocellular carcinoma; long noncoding RNA; microRNA; noncoding RNA

Indexed keywords

BIOLOGICAL MARKER; LONG UNTRANSLATED RNA; MICRORNA; UNTRANSLATED RNA;

ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; GENE CONTROL; GENE EXPRESSION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; RNA BINDING; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENETICS; LIVER NEOPLASMS; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PROGNOSIS;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; HUMANS; LIVER NEOPLASMS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RNA, LONG NONCODING; RNA, UNTRANSLATED;

EID: 84928533000     PISSN: 02728087     EISSN: 10988971     Source Type: Journal    
DOI: 10.1055/s-0034-1397350     Document Type: Article

References (164)

1. Chun J. M., Kwon H. J., Sohn J., et al. Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol: 2011; 103 2 148 151
2. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin: 2011; 61 2 69 90
3. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet: 2011; 12 12 861 874
4. Mattick J. S., Makunin I. V. Non-coding RNA. Hum Mol Genet: 2006; 15 (Spec No 1): R17 R29
5. Braconi C., Valeri N., Kogure T., et al. Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A: 2011; 108 2 786 791
6. Morris K. V., Ed. Non-Coding RNAs and Epigenetic Regulation of Gene Expression: Drivers of Natural Selection. Norfolk, England Caister Academic Press: 2012
7. Qu Z., Adelson D. L. Evolutionary conservation and functional roles of ncRNA. Front Genet: 2012; 3 205
8. Shukla G. C., Singh J., Barik S. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol: 2011; 3 3 83 92
9. Bartel D. P. MicroRNAs: target recognition and regulatory functions. Cell: 2009; 136 2 215 233
10. Sassen S., Miska E. A., Caldas C. MicroRNA: implications for cancer. Virchows Arch: 2008; 452 1 1 10
11. Li C., Feng Y., Coukos G., Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J: 2009; 11 4 747 757
12. Holland B., Wong J., Li M., Rasheed S. Identification of human microRNA-like sequences embedded within the protein-encoding genes of the human immunodeficiency virus. PLoS ONE: 2013; 8 3 e58586
13. Selbach M., Schwanhäusser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature: 2008; 455 7209 58 63
14. Di Leva G., Garofalo M., Croce C. M. MicroRNAs in cancer. Annu Rev Pathol: 2014; 9 287 314
15. Braconi C., Henry J. C., Kogure T., Schmittgen T., Patel T. The role of microRNAs in human liver cancers. Semin Oncol: 2011; 38 6 752 763
16. Lujambio A., Lowe S. W. The microcosmos of cancer. Nature: 2012; 482 7385 347 355
17. Chu R., Mo G., Duan Z., et al. miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal: 2014; 12 45
18. Datta J., Kutay H., Nasser M. W., et al. Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res: 2008; 68 13 5049 5058
19. Fang Y., Xue J. L., Shen Q., Chen J., Tian L. MicroRNA-7 inhibits tumor growth and metastasis by targeting the phosphoinositide 3-kinase/Akt pathway in hepatocellular carcinoma. Hepatology: 2012; 55 6 1852 1862
20. Wang Y., Jiang L., Ji X., Yang B., Zhang Y., Fu X. D. Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes. J Biol Chem: 2013; 288 25 18484 18493
21. Bonci D., Coppola V., Musumeci M., et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med: 2008; 14 11 1271 1277
22. Chen L., Jiang M., Yuan W., Tang H. miR-17-5p as a novel prognostic marker for hepatocellular carcinoma. J Invest Surg: 2012; 25 3 156 161
23. Murakami Y., Yasuda T., Saigo K., et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene: 2006; 25 17 2537 2545
24. Li Y., Tan W., Neo T. W., et al. Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci: 2009; 100 7 1234 1242
25. Tan W., Li Y., Lim S. G., Tan T. M. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol: 2014; 20 20 5962 5972
26. Meng F., Henson R., Wehbe-Janek H., Ghoshal K., Jacob S. T., Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology: 2007; 133 2 647 658
27. Zhou L., Yang Z. X., Song W. J., et al. MicroRNA-21 regulates the migration and invasion of a stem-like population in hepatocellular carcinoma. Int J Oncol: 2013; 43 2 661 669
28. Su Z. X., Zhao J., Rong Z. H., Geng W. M., Wu Y. G., Qin C. K. Upregulation of microRNA-25 associates with prognosis in hepatocellular carcinoma. Diagn Pathol: 2014; 9 47
29. Kota J., Chivukula R. R., O'Donnell K. A., et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell: 2009; 137 6 1005 1017
30. Yang X., Zhang X. F., Lu X., et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cMet pathway. Hepatology: 2014; 59 5 1874 1885
31. Xiong Y., Fang J. H., Yun J. P., et al. Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology: 2010; 51 3 836 845
32. Parpart S., Roessler S., Dong F., et al. Modulation of miR-29 expression by α-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology: 2014; 60 3 872 883
33. Xie K., Liu J., Chen J., et al. Methylation-associated silencing of microRNA-34b in hepatocellular carcinoma cancer. Gene: 2014; 543 1 101 107
34. Li N., Fu H., Tie Y., et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett: 2009; 275 1 44 53
35. Aguda B. D., Kim Y., Piper-Hunter M. G., Friedman A., Marsh C. B. MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A: 2008; 105 50 19678 19683
36. Xu D., He X. X., Chang Y., Sun S. Z., Xu C. R., Lin J. S. Downregulation of MiR-93 expression reduces cell proliferation and clonogenicity of HepG2 cells. Hepatogastroenterology: 2012; 59 120 2367 2373
37. Shen G., Jia H., Tai Q., Li Y., Chen D. miR-106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma. Carcinogenesis: 2013; 34 1 211 219
38. Gramantieri L., Ferracin M., Fornari F., et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res: 2007; 67 13 6092 6099
39. Tsai W. C., Hsu S. D., Hsu C. S., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest: 2012; 122 8 2884 2897
40. Zheng F., Liao Y. J., Cai M. Y., et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. Gut: 2012; 61 2 278 289
41. Lu Y., Yue X., Cui Y., Zhang J., Wang K. MicroRNA-124 suppresses growth of human hepatocellular carcinoma by targeting STAT3. Biochem Biophys Res Commun: 2013; 441 4 873 879
42. Kim J. K., Noh J. H., Jung K. H., et al. Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology: 2013; 57 3 1055 1067
43. Gong J., Zhang J. P., Li B., et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene: 2013; 32 25 3071 3079
44. Chen H., Miao R., Fan J., et al. Decreased expression of miR-126 correlates with metastatic recurrence of hepatocellular carcinoma. Clin Exp Metastasis: 2013; 30 5 651 658
45. Wei X., Tan C., Tang C., et al. Epigenetic repression of miR-132 expression by the hepatitis B virus x protein in hepatitis B virus-related hepatocellular carcinoma. Cell Signal: 2013; 25 5 1037 1043
46. Zhao J., Wang W., Huang Y., et al. HBx elevates oncoprotein AEG-1 expression to promote cell migration by downregulating miR-375 and miR-136 in malignant hepatocytes. DNA Cell Biol: 2014; 33 10 715 722
47. Liu Y., Ding Y., Huang J., et al. MiR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS ONE: 2014; 9 2 e88393
48. Wang Y., Hu C., Cheng J., et al. MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling. Biochem Biophys Res Commun: 2014; 446 4 1255 1260
49. Yang X. W., Zhang L. J., Huang X. H., et al. miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res: 2014; 44 5 551 559
50. Zhu K., Pan Q., Zhang X., et al. MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. Carcinogenesis: 2013; 34 9 2071 2079
51. Gailhouste L., Gomez-Santos L., Hagiwara K., et al. miR-148a plays a pivotal role in the liver by promoting the hepatospecific phenotype and suppressing the invasiveness of transformed cells. Hepatology: 2013; 58 3 1153 1165
52. Zhang Z., Zheng W., Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol: 2014; 31 6 984
53. Zhang Y., Wei W., Cheng N., et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology: 2012; 56 5 1631 1640
54. Wang R., Zhao N., Li S., et al. MicroRNA-195 suppresses angiogenesis and metastasis of hepatocellular carcinoma by inhibiting the expression of VEGF, VAV2, and CDC42. Hepatology: 2013; 58 2 642 653
55. Xu T., Zhu Y., Xiong Y., Ge Y. Y., Yun J. P., Zhuang S. M. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology: 2009; 50 1 113 121
56. Tan S., Li R., Ding K., Lobie P. E., Zhu T. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway. FEBS Lett: 2011; 585 14 2229 2234
57. Jiang J., Gusev Y., Aderca I., et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res: 2008; 14 2 419 427
58. Fornari F., Milazzo M., Chieco P., et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res: 2010; 70 12 5184 5193
59. Zhang L., Yang F., Yuan J. H., et al. Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis: 2013; 34 3 577 586
60. Xia H., Ooi L. L., Hui K. M. MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer. Hepatology: 2013; 58 2 629 641
61. Park J. K., Kogure T., Nuovo G. J., et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res: 2011; 71 24 7608 7616
62. Pineau P., Volinia S., McJunkin K., et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A: 2010; 107 1 264 269
63. Wong Q. W., Ching A. K., Chan A. W., et al. MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling. Clin Cancer Res: 2010; 16 3 867 875
64. Yang Y. F., Wang F., Xiao J. J., et al. MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27. Int J Clin Exp Med: 2014; 7 4 893 902
65. Dong Y. W., Wang R., Cai Q. Q., et al. Sulfatide epigenetically regulates miR-223 and promotes the migration of human hepatocellular carcinoma cells. J Hepatol: 2014; 60 4 792 801
66. Zhang Y., Takahashi S., Tasaka A., Yoshima T., Ochi H., Chayama K. Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol: 2013; 28 3 565 575
67. Yu L., Zhang J., Guo X., Li Z., Zhang P. MicroRNA-224 upregulation and AKT activation synergistically predict poor prognosis in patients with hepatocellular carcinoma. Cancer Epidemiol: 2014; 38 4 408 413
68. Buurman R., Gürlevik E., Schäffer V., et al. Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology: 2012; 143 3 811 20.e1, 15
69. Fornari F., Milazzo M., Chieco P., et al. In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. J Pathol: 2012; 227 3 275 285
70. Guerrieri F., Belloni L., Pediconi N., Levrero M. Molecular mechanisms of HBV-associated hepatocarcinogenesis. Semin Liver Dis: 2013; 33 2 147 156
71. Liu W. H., Yeh S. H., Chen P. J. Role of microRNAs in hepatitis B virus replication and pathogenesis. Biochim Biophys Acta: 2011; 1809 11-12 678 685
72. Liu W. H., Yeh S. H., Lu C. C., et al. MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology: 2009; 136 2 683 693
73. Zhang X., Zhang E., Ma Z., et al. Modulation of hepatitis B virus replication and hepatocyte differentiation by MicroRNA-1. Hepatology: 2011; 53 5 1476 1485
74. Vezali E., Aghemo A., Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther: 2010; 32 13 2117 2138
75. Rehm J., Taylor B., Mohapatra S., et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev: 2010; 29 4 437 445
76. Thorgeirsson S. S., Grisham J. W. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet: 2002; 31 4 339 346
77. Ozen C., Yildiz G., Dagcan A. T., et al. Genetics and epigenetics of liver cancer. New Biotechnol: 2013; 30 4 381 384
78. Wang B., Majumder S., Nuovo G., et al. Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology: 2009; 50 4 1152 1161
79. Perkel J. M. Visiting noncodarnia Biotechniques: 2013; 54 6 301 304, 303-304
80. Li C. H., Chen Y. Targeting long non-coding RNAs in cancers: progress and prospects. Int J Biochem Cell Biol: 2013; 45 8 1895 1910
81. Mercer T. R., Dinger M. E., Mattick J. S. Long non-coding RNAs: insights into functions. Nat Rev Genet: 2009; 10 3 155 159
82. Derrien T., Johnson R., Bussotti G., et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression. Genome Res: 2012; 22 9 1775 1789
83. Yan B., Wang Z. H., Guo J. T. The research strategies for probing the function of long noncoding RNAs. Genomics: 2012; 99 2 76 80
84. Takahashi K., Yan I. K., Haga H., Patel T. Modulation of hypoxia-signaling pathways by extracellular linc-RoR. J Cell Sci: 2014; 127 (Pt 7): 1585 1594
85. Zhao Y., Guo Q., Chen J., Hu J., Wang S., Sun Y. Role of long non-coding RNA HULC in cell proliferation, apoptosis and tumor metastasis of gastric cancer: a clinical and in vitro investigation. Oncol Rep: 2014; 31 1 358 364
86. Xie H., Ma H., Zhou D. Plasma HULC as a promising novel biomarker for the detection of hepatocellular carcinoma. Biomed Res Int: 2013; 2013 136106
87. Hämmerle M., Gutschner T., Uckelmann H., et al. Posttranscriptional destabilization of the liver-specific long noncoding RNA HULC by the IGF2 mRNA-binding protein 1 (IGF2BP1). Hepatology: 2013; 58 5 1703 1712
88. Du Y., Kong G., You X., et al. Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem: 2012; 287 31 26302 26311
89. Wang J., Liu X., Wu H., et al. CREB up-regulates long non-coding RNA, HULC expression through interaction with microRNA-372 in liver cancer. Nucleic Acids Res: 2010; 38 16 5366 5383
90. He Y., Meng X. M., Huang C., et al. Long noncoding RNAs: novel insights into hepatocellular carcinoma. Cancer Lett: 2014; 344 1 20 27
91. Yang F., Zhang L., Huo X. S., et al. Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology: 2011; 54 5 1679 1689
92. Anwar S. L., Krech T., Hasemeier B., et al. Loss of imprinting and allelic switching at the DLK1-MEG3 locus in human hepatocellular carcinoma. PLoS ONE: 2012; 7 11 e49462
93. Braconi C., Kogure T., Valeri N., et al. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene: 2011; 30 47 4750 4756
94. Nie F. Q., Zhu Q., Xu T. P., et al. Long non-coding RNA MVIH indicates a poor prognosis for non-small cell lung cancer and promotes cell proliferation and invasion. Tumour Biol: 2014; 35 8 7587 7594
95. Yuan S. X., Yang F., Yang Y., et al. Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. Hepatology: 2012; 56 6 2231 2241
96. Tsang W. P., Wong T. W., Cheung A. H., Co C. N., Kwok T. T. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA: 2007; 13 6 890 898
97. Shi X., Sun M., Liu H., Yao Y., Song Y. Long non-coding RNAs: a new frontier in the study of human diseases. Cancer Lett: 2013; 339 2 159 166
98. Lv J., Yu Y. Q., Li S. Q., Luo L., Wang Q. Aflatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1. Asian Pac J Cancer Prev: 2014; 15 6 2565 2570
99. Tsang W. P., Kwok T. T. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene: 2007; 26 33 4877 4881
100. Gabory A., Jammes H., Dandolo L. The H19 locus: role of an imprinted non-coding RNA in growth and development. BioEssays: 2010; 32 6 473 480
101. Iizuka N., Oka M., Yamada-Okabe H., et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res: 2002; 62 14 3939 3944
102. Ariel I., Miao H. Q., Ji X. R., et al. Imprinted H19 oncofetal RNA is a candidate tumour marker for hepatocellular carcinoma. Mol Pathol: 1998; 51 1 21 25
103. Geng Y. J., Xie S. L., Li Q., Ma J., Wang G. Y. Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res: 2011; 39 6 2119 2128
104. Yang Z., Zhou L., Wu L. M., et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann Surg Oncol: 2011; 18 5 1243 1250
105. Ishibashi M., Kogo R., Shibata K., et al. Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma. Oncol Rep: 2013; 29 3 946 950
106. Ding C., Cheng S., Yang Z., et al. Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells. Int J Mol Sci: 2014; 15 3 4060 4076
107. Quagliata L., Matter M. S., Piscuoglio S., et al. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology: 2014; 59 3 911 923
108. Lai M. C., Yang Z., Zhou L., et al. Long non-coding RNA MALAT-1 overexpression predicts tumor recurrence of hepatocellular carcinoma after liver transplantation. Med Oncol: 2012; 29 3 1810 1816
109. Lin R., Maeda S., Liu C., Karin M., Edgington T. S. A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene: 2007; 26 6 851 858
110. Takahashi K., Yan I. K., Kogure T., Haga H., Patel T. Extracellular vesicle-mediated transfer of long non-coding RNA ROR modulates chemosensitivity in human hepatocellular cancer. FEBS Open Bio: 2014; 4 458 467
111. Hou P., Zhao Y., Li Z., et al. LincRNA-ROR induces epithelial-to-mesenchymal transition and contributes to breast cancer tumorigenesis and metastasis. Cell Death Dis: 2014; 5 e1287
112. Yuan J. H., Yang F., Wang F., et al. A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell: 2014; 25 5 666 681
113. Takahashi K., Yan I., Haga H., Patel T. Long noncoding RNA in liver diseases. Hepatology: 2014; 60 2 744 753
114. Carninci P., Kasukawa T., Katayama S., et al. FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The transcriptional landscape of the mammalian genome. Science: 2005; 309 5740 1559 1563
115. Guttman M., Amit I., Garber M., et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature: 2009; 458 7235 223 227
116. Wang Z., Li X. The role of noncoding RNA in hepatocellular carcinoma. Gland Surg: 2013; 2 1 25 29
117. Panzitt K., Tschernatsch M. M., Guelly C., et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology: 2007; 132 1 330 342
118. Bejerano G., Pheasant M., Makunin I., et al. Ultraconserved elements in the human genome. Science: 2004; 304 5675 1321 1325
119. Calin G. A., Liu C. G., Ferracin M., et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell: 2007; 12 3 215 229
120. Mestdagh P., Fredlund E., Pattyn F., et al. An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene: 2010; 29 24 3583 3592
121. Kogure T., Yan I. K., Lin W. L., Patel T. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer: 2013; 4 7-8 261 272
122. Li W., Xie L., He X., et al. Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer: 2008; 123 7 1616 1622
123. Borel F., Konstantinova P., Jansen P. L. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol: 2012; 56 6 1371 1383
124. Hou W., Bonkovsky H. L. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy. World J Gastroenterol: 2013; 19 44 7836 7845
125. Xiao F., Zhang W., Zhou L., et al. microRNA-200a is an independent prognostic factor of hepatocellular carcinoma and induces cell cycle arrest by targeting CDK6. Oncol Rep: 2013; 30 5 2203 2210
126. Lv Z., Wei Y., Wang D., Zhang C. Y., Zen K., Li L. Argonaute 2 in cell-secreted microvesicles guides the function of secreted miRNAs in recipient cells. PLoS ONE: 2014; 9 7 e103599
127. Cereghetti D. M., Lee P. P. Tumor-derived exosomes contain microRNAs with immunological function: implications for a novel immunosuppression mechanism. Microrna: 2014; 2 3 194 204
128. Kogure T., Lin W. L., Yan I. K., Braconi C., Patel T. Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology: 2011; 54 4 1237 1248
129. Diaz G., Melis M., Tice A., et al. Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma. Int J Cancer: 2013; 133 4 816 824
130. Varnholt H., Drebber U., Schulze F., et al. MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology: 2008; 47 4 1223 1232
131. Abdalla M. A., Haj-Ahmad Y. Promising candidate urinary microrna biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer: 2012; 3 19 31
132. Fu Y., Wei X., Tang C., et al. Circulating microRNA-101 as a potential biomarker for hepatitis B virus-related hepatocellular carcinoma. Oncol Lett: 2013; 6 6 1811 1815
133. Hou J., Lin L., Zhou W., et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell: 2011; 19 2 232 243
134. Karakatsanis A., Papaconstantinou I., Gazouli M., Lyberopoulou A., Polymeneas G., Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog: 2013; 52 4 297 303
135. Xie K., Liu J., Zhu L., et al. A potentially functional polymorphism in the promoter region of let-7 family is associated with survival of hepatocellular carcinoma. Cancer Epidemiol: 2013; 37 6 998 1002
136. Xu Y., Liu L., Liu J., et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer: 2011; 128 2 412 417
137. Liang T. J., Liu H. J., Zhao X. Q., Yu C. H., Li C. S. Lack of association of MiR-34b/c polymorphism (rs4938723) with hepatocellular carcinoma: a meta-analysis. PLoS ONE: 2013; 8 7 e68588
138. Son M. S., Jang M. J., Jeon Y. J., et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene: 2013; 524 2 156 160
139. Tao T., Chen S., Xu B., et al. Association between hsa-miR-34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls. Chin J Cancer Res: 2014; 26 3 315 322
140. Bae J. S., Kim J. H., Pasaje C. F., et al. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis: 2012; 44 10 849 854
141. Liu Y., Zhang Y., Wen J., et al. A genetic variant in the promoter region of miR-106b-25 cluster and risk of HBV infection and hepatocellular carcinoma. PLoS ONE: 2012; 7 2 e32230
142. Qi F., Huang M., Pan Y., et al. A genetic variant in the promoter region of miR-106b-25 cluster predict clinical outcome of HBV-related hepatocellular carcinoma in Chinese. PLoS ONE: 2014; 9 1 e85394
143. Akklz H., Bayram S., Bekar A., Akgöllü E., Usküdar O., Sandlkçl M. No association of pre-microRNA-146a rs2910164 polymorphism and risk of hepatocellular carcinoma development in Turkish population: a case-control study. Gene: 2011; 486 1-2 104 109
144. Xiang Y., Fan S., Cao J., Huang S., Zhang L. P. Association of the microRNA-499 variants with susceptibility to hepatocellular carcinoma in a Chinese population. Mol Biol Rep: 2012; 39 6 7019 7023
145. Zhou B., Dong L. P., Jing X. Y., et al. Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol: 2014; 35 8 7775 7780
146. Kim W. H., Min K. T., Jeon Y. J., et al. Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene: 2012; 504 1 92 97
147. Kou J. T., Fan H., Han D., et al. Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection. Oncol Lett: 2014; 8 3 1255 1260
148. Wang X. H., Wang F. R., Tang Y. F., Zou H. Z., Zhao Y. Q. Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genet Mol Res: 2014; 13 3 5048 5054
149. Li X. D., Li Z. G., Song X. X., Liu C. F. A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology: 2010; 42 7 669 673
150. Akklz H., Bayram S., Bekar A., Akgöllü E., Ulger Y. A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepat: 2011; 18 7 e399 e407
151. Guo J., Jin M., Zhang M., Chen K. A genetic variant in miR-196a2 increased digestive system cancer risks: a meta-analysis of 15 case-control studies. PLoS ONE: 2012; 7 1 e30585
152. Kim H. Y., Yoon J. H., Lee H. S., et al. MicroRNA-196A-2 polymorphisms and hepatocellular carcinoma in patients with chronic hepatitis B. J Med Virol: 2014; 86 3 446 453
153. Kwak M. S., Lee D. H., Cho Y., et al. Association of polymorphism in pri-microRNAs-371-372-373 with the occurrence of hepatocellular carcinoma in hepatitis B virus infected patients. PLoS ONE: 2012; 7 7 e41983
154. Akkiz H., Bayram S., Bekar A., Akgöllü E., Üsküdar O. Genetic variation in the microRNA-499 gene and hepatocellular carcinoma risk in a Turkish population: lack of any association in a case-control study. Asian Pac J Cancer Prev: 2011; 12 11 3107 3112
155. Liu Y., Pan S., Liu L., et al. A genetic variant in long non-coding RNA HULC contributes to risk of HBV-related hepatocellular carcinoma in a Chinese population. PLoS ONE: 2012; 7 4 e35145
156. Cheetham S. W., Gruhl F., Mattick J. S., Dinger M. E. Long noncoding RNAs and the genetics of cancer. Br J Cancer: 2013; 108 12 2419 2425
157. Braconi C., Patel T. Non-coding RNAs as therapeutic targets in hepatocellular cancer. Curr Cancer Drug Targets: 2012; 12 9 1073 1080
158. Chen Z., Ma T., Huang C., et al. MicroRNA-148a: a potential therapeutic target for cancer. Gene: 2014; 533 1 456 457
159. D'Anzeo M., Faloppi L., Scartozzi M., et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules: 2014; 19 5 6393 6406
160. Tomimaru Y., Eguchi H., Nagano H., et al. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer: 2010; 103 10 1617 1626
161. Henke J. I., Goergen D., Zheng J., et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J: 2008; 27 24 3300 3310
162. Lanford R. E., Hildebrandt-Eriksen E. S., Petri A., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science: 2010; 327 (5962): 198 201
163. Ebert M. S., Neilson J. R., Sharp P. A. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods: 2007; 4 9 721 726
164. Sun B. S., Dong Q. Z., Ye Q. H., et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology: 2008; 48 6 1834 1842